Hematopoietic Cell Transplantation - Comorbidity Index (Hct-Ci) As A Surrgoate Marker For Predition Of Transplant Outcome For Pateints (Pts) With Multiple Myeloma (Mm) Undergoing Autologous Stem Cell Transplantation (Asct): High Hct-Ci Score Predicts For Poor Outcome

Background: For all “transplant eligible” pts with MM, established practice guidelines recommend ASCT as part of the front line treatment. However, the definition of “transplant eligible” remains undefined. The HCT-CI is a new tool that encapsulates pre-transplant comorbidities used in predicting transplant outcomes in pts undergoing allogeneic SCT. This scoring system has been shown to be a good predictor for non-relapse mortality (NRM) & survival in pts undergoing alloSCT. In this study, we hypothesize that HCT-CI could predict the transplant outcome on pts with MM undergoing ASCT and could potentially be utilized as a tool for selecting pts with MM for transplant.